What actually separates real AI progress in drug discovery from the hype?
In a new interview with CanadianSME AI Business Review, our own Anne Fortier, VP of Drug Discovery and Development at Conscience, tackles that question head-on. She talks about where AI is already making a measurable difference (clinical trial recruitment and hit-finding lead the pack), why so many promising AI pilots in pharma never make it past the pilot stage, and why rigorous, shared benchmarking is what will actually move the field forward.
Anne also breaks down what makes a proposal stand out in our own funding programs: open, FAIR data, a clearly defined unmet need, and a credible path to real-world impact.
